Tactile Systems

Tactile Systems Technology, Inc. is a medical technology company. It develops and provides innovative medical devices for the treatment of chronic diseases at home. The firm focus on advancing the standard of care in treating chronic diseases in the home setting to improve patient outcomes and quality of life and help control rising healthcare expenditures. The company was founded on January 30, 1995 and is headquartered in Minneapolis, MN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Tactile Systems reports strong Q4 earnings, eyes growth and innovation

Tactile Systems delivered impressive Q4 2022 results with strong revenue growth, positive net income, and operational advancements, positioning the company for future success.
Strategic priorities for 2023 focus on sales team productivity, new product innovation, and operational efficiency, highlighting a commitment to sustained growth and market leadership.
Challenges include managing sales force turnover, supply chain constraints, and financial complexities post-2023, requiring proactive solutions and strategic decision-making.
Opportunities lie in capitalizing on revenue growth momentum, new product developments, and achieving an expanded adjusted EBITDA profile, signaling potential for continued success and value creation.

Tactile Systems reports robust Q1 growth, focuses on innovation

Tactile Systems delivered strong financial performance and operational advancements in Q1 2023, showcasing growth potential and a commitment to innovation and patient care.
While facing challenges in supply chain readiness and operational efficiency, the company's strategic focus on enhancing Medicare processes and product development presents opportunities for future success.
Overall, Tactile Systems' earnings call highlighted a positive trajectory with increased revenue guidance, product innovation, and a dedication to improving patient outcomes and support.

Tactile Systems (TCMD) reports strong Q2 earnings and growth outlook

Tactile Systems (TCMD) showcased robust financial performance, operational efficiency gains, and strategic talent additions in Q2 2023.
While facing challenges like AffloVest sales slowdown, the company raised revenue guidance and expects strong profitability with adjusted EBITDA of $25-27 million for 2023.
Opportunities lie in the head and neck trial's potential impact on revenue, Kylee app engagement benefits, and strategic priorities driving growth.

Tactile Systems reports revenue growth and strategic initiatives progress

Tactile Systems' Q3 performance showed revenue growth and improved profitability, supported by strategic initiatives and margin improvement efforts.
While facing challenges in AffloVest sales and patient acquisition, the company is optimistic about opportunities in therapy expansion and operational enhancements.
Consistent price increases and focus on technology-driven efficiencies are key strengths, with a focus on achieving ambitious 2025 targets.
Overall, Tactile Systems is navigating challenges while capitalizing on opportunities for growth and operational optimization.

Tactile Systems posts robust Q4 results, eyes growth opportunities

Tactile Systems delivered strong financial performance in Q4 2023, with revenue and net income growth. The company provided optimistic revenue guidance for 2024 and outlined strategic priorities for driving growth and enhancing customer experience. Challenges include anticipated headwinds and limited margin gains in the short term.

Tactile Systems reports Q1 growth, doubles EBITDA, eyes tech expansion

Tactile Systems reported solid financial performance with revenue growth and doubled adjusted EBITDA.
The company is strategically investing in tech advancements, new products, and expanding sales channels.
Challenges include addressing declining airway clearance revenues and optimizing sales rep impact.
Opportunities lie in expanding clinical trials, enhancing product user experience, and leveraging tech investments.

Tactile Systems (TCMD) reports robust Q2 earnings amidst Medicare challenges

Tactile Systems' Q2 2024 performance reflects solid financial growth and strategic initiatives. While facing challenges from Medicare documentation requirements, the company is focused on adapting to regulatory changes. Opportunities lie in capital allocation strategies, technology advancements, and market expansion efforts.

Tactile Systems reports Q3 growth, faces documentation challenges and opportunities

Tactile Systems delivered solid Q3 performance with revenue growth and improved EBITDA, despite challenges in sales productivity.
The company's strategic strengths lie in strong market demand, product innovation, and a shareholder-friendly capital allocation strategy.
Navigating challenges related to regulatory changes and operational efficiency while capitalizing on growth opportunities will be key for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tactile Systems Technology, Inc. engages in developing and providing medical devices for the treatment of underserved chronic diseases. It provides lymphedema solutions and offers Flexitouch Plus and Entre Plus systems products. The company was founded on January 30, 1995 and is headquartered in Minneapolis, MN.

MINNEAPOLIS, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq:TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today announced that management will participate in the Morgan Stanley 20th Annual Global Healthcare Conference, which is being held at the Sheraton New York Times Square Hotel in New York, NY from September 12th-14th. Management will participate in a fireside chat on Tuesday, September 13th at 11:10 a.m. Eastern Time.

Tactile Medical to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Tactile Systems Technology, Inc. (NASDAQ:TCMD ) Q2 2022 Earnings Conference Call August 1, 2022 5:00 PM ET Company Participants Dan Reuvers - President and CEO Brent Moen - CFO Conference Call Participants Ryan Zimmerman - BTIG Simran Kaur - Piper Sandler Margaret Kaczor - William Blair Suraj Kalia - Oppenheimer & Company Operator Welcome ladies and gentlemen to the Second Quarter of Fiscal Year 2022 Earnings Conference Call for Tactile Medical. At this time, all participants have been placed in a listen-only mode.

Tactile Systems Technology, Inc. (TCMD) CEO Dan Reuvers on Q2 2022 Results - Earnings Call Transcript

Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of 12.50% and 4.81%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Tactile Systems Technology (TCMD) Reports Q2 Loss, Tops Revenue Estimates

Second Quarter Revenue Increased 17% Year-Over-Year; First Half Revenue Increased 15% Year-Over-Year Second Quarter Revenue Increased 17% Year-Over-Year; First Half Revenue Increased 15% Year-Over-Year

Tactile Systems Technology, Inc. Reports Second Quarter 2022 Financial Results; Raises Full Year 2022 Outlook

Flexitouch Plus garments redesigned to improve the patient experience; the Kylee app empowers patients through digital health monitoring Flexitouch Plus garments redesigned to improve the patient experience; the Kylee app empowers patients through digital health monitoring

Tactile Medical Introduces New ComfortEase™ Flexitouch® Plus Garments and Kylee™ Mobile Application

MINNEAPOLIS, July 12, 2022 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq:TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today announced that second quarter of fiscal year 2022 financial results will be released after the market closes on Monday, August 1st.

Tactile Medical to Release Second Quarter of Fiscal Year 2022 Financial Results on August 1, 2022

Wilmington, Delaware--(Newsfile Corp. - June 29, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Tactile Systems Technology, Inc. (NASDAQ: TCMD) on behalf of stockholders.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-tactile-systems-technology-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Tactile Systems Technology, Inc.

VAALCO Energy

Franklin BSP Realty Trust Inc

Kezar Life Sciences Inc

Millennium Management's Israel Englander is in focus after the billionaire's fund purchased several stocks this month. The post Billionaire Israel Englander Is Betting Big on These 5 Stocks appeared first on InvestorPlace.

Billionaire Israel Englander Is Betting Big on These 5 Stocks

Consensus that Patients with Chronic Venous Insufficiency Should be Considered Lymphedema Patients Consensus that Patients with Chronic Venous Insufficiency Should be Considered Lymphedema Patients

Tactile Medical Announces Publication of Expert Opinion Consensus Statement in Phlebology Recommending the Use of Pneumatic Compression for Lymphedema

MINNEAPOLIS, May 25, 2022 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq:TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today announced that management will participate in the William Blair 42nd Annual Growth Stock Conference, which is being held at the Loews Chicago Hotel in Chicago, Il from June 6th-9th. Management will host a presentation with investors followed by a breakout session on Tuesday, June 7th at 1:20 p.m. Central Time.

Tactile Medical to Present at the William Blair 42nd Annual Growth Stock Conference

Philadelphia, Pennsylvania--(Newsfile Corp. - May 9, 2022) - Claims alleged in a class action lawsuit that was filed in 2020 against Tactile Systems Technology, Inc. (NASDAQ: TCMD) have survived a motion to dismiss. The complaint alleges that Tactile made a number of materially false and misleading statements relating to the market for and sales of its pneumatic compression devices ("PCD") for at home treatment of lymphedema and chronic venous insufficiency ("CVI") and revenue growth...

Grabar Law Office Investigates Potential Shareholder Action on Behalf of Current Shareholders of Tactile Systems Technology, Inc. After Class Action Claims Survive Motion to Dismiss

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Tactile Systems Technology, Inc. (NasdaqGM: TCMD). On June 8, 2020, the Company was the target of a investigative report published by research firm OSS Research accusing it of overstating its total addressable market by nearly $4.7 billion, using a “daisy-chaining kick-back scheme” res

TACTILE SYSTEMS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Tactile Systems Technology, Inc. - TCMD

Philadelphia, Pennsylvania--(Newsfile Corp. - May 3, 2022) - A class action lawsuit that was filed in 2020 against Tactile Systems Technology, Inc. (NASDAQ: TCMD) has survived a motion to dismiss. The complaint alleges that Tactile made a number of materially false and misleading statements relating to the market for and sales of its pneumatic compression devices ("PCD") for at home treatment of lymphedema and chronic venous insufficiency ("CVI") and revenue growth and drivers.Tactile shareholders...

Grabar Law Office Investigates Potential Shareholder Action on Behalf of Current Shareholders of Tactile Systems Technology, Inc. (TCMD) After Class Action Partially Survives Motion to Dismiss

Tactile Systems Technology, Inc. (NASDAQ:TCMD ) Q1 2022 Earnings Conference Call May 2, 2022 5:00 PM ET Company Participants Dan Reuvers - President and CEO Brent Moen - CFO Conference Call Participants Ryan Zimmerman - BTIG Adam Mandel - Piper Sandler Suraj Kalia - Oppenheimer Maggie Boeye - William Blair Operator Welcome ladies and gentlemen to the First Quarter of Fiscal Year 2022 Earnings Conference call for Tactile Medical. At this time, all participants have been placed in a listen-only mode.

Tactile Systems Technology, Inc. (TCMD) CEO Dan Reuvers on Q1 2022 Results - Earnings Call Transcript

First Quarter Revenue Increased 12% Year-Over-Year First Quarter Revenue Increased 12% Year-Over-Year

Tactile Systems Technology, Inc. Reports First Quarter 2022 Financial Results; Reaffirms Full Year 2022 Outlook

Avation Medical appoints Darren Wennen, a medical industry veteran, as Chief Marketing Officer in anticipation of commercialization of its wearable neuromodulation system to treat OAB and UUI. COLUMBUS, Ohio , April 13, 2022 /PRNewswire/ -- Avation Medical, an innovative neuromodulation and digital health company pioneering a wearable system to treat the symptoms of overactive bladder (OAB) and urge urinary incontinence (UUI), today announced the appointment of Darren Wennen as its Chief Marketing Officer.

Avation Medical Announces Appointment of Chief Marketing Officer to Executive Leadership Team

MINNEAPOLIS, March 07, 2022 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq:TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today announced that management will participate in Oppenheimer's 32nd Annual Healthcare Conference, which is being held virtually from March 15th-16th. Management will participate in a virtual fireside chat on Tuesday, March 15th at 3:20 p.m. Eastern Time and host virtual 1x1 meetings on Wednesday, March 16th.

Tactile Medical to Participate in the Oppenheimer Healthcare Conference

Tactile Systems Technology, Inc. (TCMD) CEO Dan Reuvers on Q4 2021 Results - Earnings Call Transcript

Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of -566.67% and 6.03%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Tactile Systems Technology (TCMD) Reports Q4 Loss, Tops Revenue Estimates

Fourth Quarter Revenue Increased 4% Year-Over-Year; Full Year Revenue Increased 11% Year-over-Year Fourth Quarter Revenue Increased 4% Year-Over-Year; Full Year Revenue Increased 11% Year-over-Year

Tactile Systems Technology, Inc. Reports Fourth Quarter And Full Year 2021 Financial Results; Introduces Full Year 2022 Outlook

MINNEAPOLIS, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD) announced today that the qui tam lawsuit filed by a competitor has been dropped and dismissed by a federal judge in Texas. The lawsuit challenged the propriety of Tactile Medical's patient and physician education programs. This dismissal validates Tactile Medical's longstanding confidence in the validity of our programs. Tactile Medical will not pay any damages, penalties, attorney fees or other compensation.

Tactile Medical Announces Qui Tam Lawsuit Dropped by Plaintiff

Tactile Systems Technology (TCMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Tactile Systems Technology (TCMD) to Report a Decline in Earnings: What to Look Out for

MINNEAPOLIS, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq:TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today announced that management will participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference.

Tactile Medical to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

MINNEAPOLIS, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq:TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today announced that fourth quarter and fiscal year 2021 financial results will be released after the market closes on Tuesday, February 22nd.

Tactile Medical to Release Fourth Quarter and Fiscal Year 2021 Financial Results on February 22, 2022

Appoints Valerie Asbury and Brent Shafer Appoints Valerie Asbury and Brent Shafer

News for Tactile Systems Stock (TCMD)